A Novel CDC42 Variant with Impaired Thymopoiesis, IL-7R Signaling, PAK1 Binding, and TCR Repertoire Diversity

J Clin Immunol. 2023 Nov;43(8):1927-1940. doi: 10.1007/s10875-023-01561-0. Epub 2023 Aug 15.

Abstract

Genetic variants in cell division cycle 42 (CDC42) can manifest with dysmorphic features, autoinflammation, hemophagocytic lymphohistiocytosis, and thrombocytopenia, whereas defective thymopoiesis is a rare disease manifestation. We report a novel CDC42 missense variant (c.46A > G, p.Lys16Glu) resulting in infection and HPV-driven carcinogenesis in the mosaic mother and impaired thymopoiesis and profound T cell lymphopenia in the heterozygous daughter identified through newborn screening for SCID. We found that surface expression of IL-7Rα (CD127) was decreased, consistent with reduced IL-7-induced STAT5 phosphorylation and accelerated apoptotic T cell death. Consistent with the vital role of IL-7 in regulating thymopoiesis, both patients displayed reduced T cell receptor CDR3 repertoires. Moreover, the CDC42 variant prevented binding to the downstream effector, p21-activated kinase (PAK)1, suggesting this impaired interaction to underlie reduced IL-7Rα expression and signaling. Here, we provide the first report of severely compromised thymopoiesis and perturbed IL-7Rα signaling caused by a novel CDC42 variant and presenting with diverging clinical and immunological phenotypes in patients.

Keywords: CDC42; HPV carcinogenesis; IL7 receptor; Inborn error of immunity; Lymphopenia; Mosaic, T cell receptor diversity; Newborn screening.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis
  • Humans
  • Infant, Newborn
  • Interleukin-7* / genetics
  • Receptors, Antigen, T-Cell / genetics
  • Signal Transduction
  • p21-Activated Kinases*

Substances

  • Interleukin-7
  • p21-Activated Kinases
  • PAK1 protein, human
  • Receptors, Antigen, T-Cell
  • CDC42 protein, human